TITLE:
Immunotherapy in Early Stage Non-Small Cell Lung Cancer
AUTHORS:
Jeyanthi Ramanarayanan, Ganapathy Krishnan
KEYWORDS:
Non-Small Cell Lung Cancer, Immunotherapy, Immune Checkpoint Inhibitors, Adjuvant, Neoadjuvant, Early Stage
JOURNAL NAME:
Advances in Lung Cancer,
Vol.11 No.3,
September
1,
2022
ABSTRACT: Immune-checkpoint inhibitors are extensively used in
cancer treatment and have transformed the therapeutic landscape by inducing
durable responses. Immunotherapy with checkpoint inhibitors targeting
programmed death 1 (PD-1) receptor and programmed death ligand-1 (PDL-1) are
used alone or with chemotherapy for treatment of metastatic non-small cell lung
cancer (NSCLC). There is a great need for improving outcomes of patients with
early stage NSCLC after surgical resection and with recent F. D. A. approval, immune checkpoint inhibitors are
used as neoadjuvant or adjuvant therapy to enable curative resection and
prevent or delay disease progression. In this article, we review the clinical studies evaluating the role of adjuvant
and neoadjuvant immune checkpoint inhibitors in NSCLC and discuss the
role of immunotherapy with radiation therapy in locally advanced non-metastatic
NSCLC.